IFG Advisory LLC Purchases 8,264 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• IFG Advisory LLC increased its stake in Johnson & Johnson by 48.2% during the first quarter, acquiring an additional 8,264 shares, bringing its total to 25,398 shares worth approximately $4.21 million.
• Several analysts have given Johnson & Johnson a consensus rating of "Moderate Buy" with a price target averaging $174.50, reflecting recent upward adjustments in their price objectives.
• The company has declared a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 3.1%, with the dividend payout ratio currently at 55.61%.

IFG Advisory LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 48.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,398 shares of the company's stock after acquiring an additional 8,264 shares during the quarter. IFG Advisory LLC's holdings in Johnson & Johnson were worth $4,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of JNJ. Conquis Financial LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $36,000. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Morgan Stanley boosted their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $174.50.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $167.33 on Friday. The company has a market cap of $402.99 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. The stock's 50 day simple moving average is $157.46 and its 200-day simple moving average is $156.60. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.82 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.1%. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.